Lung cancer has the highest possibility of death in Korea among major cancers and among lung cancer, arsenical lung cancer has the highest rate of occurrence. Among the patients of such arsenic lung cancer, the level of OPN within the plasma was high and the rate of OPN occurrence in lung cancer and transferred lung cancer organs increased. Currently there was a report that if you adapt the siRNA that sustains the OPN occurrence, it can prevent the growth of the lung cancer cell. Using such feature, we can develop a new kind of anticancer drug that has no side effect such as with the previous anticancer drugs such as siRNA. However, nucleic acid curing materials such as siRNA is hard to transfer the nucleic acid curing material that has the negative charge effectively to the cell through the cell membrane that has the negative charge and when it is injected to the body, the efficiency of the nucleic acid curing material deteriorates due to the various enzyme and it has trouble transferring it to the cells on the wanted parts and organs. In order to overcome such shortcomings, the transferring system of the nucleic acid curing material should be developed. Although it has lower transferring efficiency than the virus vector, in this study we are to develop a transferring system that uses a non-virus vector that use a much superior nana particle that has lower immunogenicity and greater features in terms of safety compared to virus vectors. In order to do this, it uses the SDA/bPEI600 which is the delivery for the developed nucleic acid curing material and in terms of the usage possibility of the anticancer delivery, it checked the efficiency evaluation of the xenograft animal model. At a state where the related efficiency was verified, the safety of SDA/bPEI600 was evaluated. For the safety evaluation, it evaluated the inheritance toxic evaluation, repeated injection toxic evaluation and the changes of the blood density within the body. As a result, the inheritance toxic for SDA/bPEI600 were negative and the from the experiment of the repeated injection toxic evaluation, there was a kidney toxic and the changes of the blood density within the body increased on terms of quantity based unit according to the increases in the injection quantity and there were no difference in the body exposure level according to the injection term and sex and also no difference among the sexes. Kidney toxic is a disease that is observed in the previous nano material and it is assumed that it is based on the general characters of the nano material and of you adjust the size of the nano particles, it can be overcome. This study checked the possibility of developing the nucleic acid curing material by the siRNA+SDA/bPEI600 and the development of the anticancer nucleic acid curing material can relieve the shortcomings of the previous anticancer material and can contribute to the medicine industry in Korea and the development of a medicine that is cheaper than the previous anticancer cures and that has a superior anticancer effect would not only improve the quality of lives of the patient and their family but also save the cost in anticancer curing in a big way and would relieve the finance of the national medical insurance and the medical cost of the patients as well. Also, by using the siRNA delivery of SDA/bPEI600, among the numerous diseases such as leukemia, it provided a possibility to develop a curing material that uses siRNA that can prevent the occurrence of a specific RNA.